

#### **DISCLAIMER**




This document contains certain forward-looking statements concerning Danone. Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the section "Risk Factors" in Danone's Registration Document (which is available on www.danone.com). Danone undertakes no obligation to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy DANONE shares.

This document refers to financial indicators that are not defined by IFRS. For a detailed description of these indicators, please refer to the section "Financial indicators not defined in IFRS" of the press releases on its results published by Danone (which are available on www.danone.com).

Due to rounding, the sum of values presented in this document may differ from totals as reported. Such differences are not material.

## A YEAR OF TURBULENCES






## **2014 KEY ACHIEVEMENTS**



#### MANAGING THE EQUATION IN EUROPE



#### **ENHANCING OUR PLATFORMS**













#### PLANTING SEEDS FOR THE FUTURE



#### **CONSOLIDATING ASIA**







### SOLID PERFORMANCE IN A VOLATILE ENVIRONMENT



	2014 targets announced FY 2013	FY 2014
Sales growth <sup>(1)</sup>	At least 4.5%	4.7%
Trading operating margin <sup>(1)</sup>	Stable ± 20bps	12.59% -12bps
Free cash-flow excluding exceptional items <sup>(2)</sup>	Around €1.5 bn	€1,401 mln

<sup>(1)</sup> Like-for-like: excludes the impact of changes in the basis for comparison, which include exchange rates and scope of consolidation

<sup>(2)</sup> Free cash-flow excluding exceptional items: represents free cash-flow before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt organization in Europe

### 2014: A YEAR OF TRANSFORMATION



#### October





New role
Strengthened duties



Thoughts and design

Set up and implementation of a new governance



## GOVERNANCE - A NEW ORGANIZATION







15 Board members 71% independent









#### GOVERNANCE – A NEW BOARD MEMBER



#### Appointment of a new Board member (independent) proposed to next AGM



2015 Board composition characteristics (subject to the approval of the Shareholders' Meeting)

- Rate of independence: 77%
- Percentage of women: 38%
- Average age of Directors: 55.4 years
- Percentage of Directors with non-French nationality: 31%

### **AGENDA**



2014: A solid performance in a volatile environment - Pierre-André Terisse, CFO

2015: Priorities and stakes – Emmanuel Faber, CEO

**Questions & Answers** 

#### **AGENDA**



2014 : A solid performance in a volatile environment - Pierre-André Terisse, CFO

2015: Priorities and stakes – Emmanuel Faber, CEO

**Questions & Answers** 

## **KEY FIGURES**



Sales	€ 21,144 mln	+4.7% like-for-like <sup>(1)</sup> (0.7)% reported
Trading operating income	€ 2,662 mln	+3.7 % like-for-like <sup>(1)</sup> (5.2)% reported
Trading operating margin	12.59%	-12 bps like-for-like <sup>(1)</sup> (60) bps reported
Underlying net income	€ 1,561 mln	+3.6% like-for-like <sup>(1) (2)</sup> (4.6)% reported
Underlying EPS (fully diluted)	€ 2.62	+2.5% like-for-like <sup>(1)</sup> (5.6)% reported
Free cash-flow excluding exceptional items <sup>(3)</sup>	€ 1,401 mln	(9.6)% reported

- (1) Like-for-like: excludes the impact of changes in the basis for comparison, which include exchange rates and scope of consolidation
- (2) Excluding non-current
- (3) Free cash-flow excluding exceptional items: represents free cash-flow before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt organization in Europe

#### 2014: KEYS TO READ OUR FINANCIAL PERFORMANCE



#### **EUROPE: SIGNS OF SUCCESS**

\* High inflation



Mix management price increase 2014

\* Margin stabilized



portfolio

## CIS: HOLDING TIGHT IN ADVERSE MARKET CONDITIONS

Milk cost













#### **ALMA: NAVIGATING IN VOLATILE MARKETS**

Forex





\* Investment

Asia

Africa





## ELN ASIA: ONE YEAR AFTER, RECOVERY WELL ADVANCED

\* Dumex slow recovery











### FY 2014 - SALES GROWTH ANALYSIS





## Q4 2014 - SALES GROWTH ANALYSIS






# TOTAL COMPANY – A SOLID PERFORMANCE IN A VOLATILE ENVIRONMENT



#### Like-for-like sales growth

Q4 2014 figures after treatment of over inflation for the full year






- Solid performance in all markets
- V-shape year after the Fonterra false alert
- Key progresses to reinforce/strengthen platforms for 2015

#### **GEOGRAPHICAL DYNAMICS**

Actual

8 recall markets








## FRESH DAIRY PRODUCTS – FOCUSING ON KEY BATTLES TO FACE EXCEPTIONAL MILK INFLATION



Price/mix

Like-for-like sales growth



- Price & mix management to offset milk inflation
- \* Adapting portfolio in all regions

## FRESH DAIRY PRODUCTS - Selected innovations Q4
















#### WATERS – SUSTAINED STRONG GROWTH








- Very solid volume dynamics in mature & emerging markets
- \* Favorable mix driven primarily by Asia & Aquadrinks development

## WATERS – Selected innovations Q4
















## EARLY LIFE NUTRITION – REBUILD STRONG PLATFORMS OF GROWTH





- \* Asia market recovery enhanced by global Internet development
- Europe solid; rest of ALMA strong




## **EARLY LIFE NUTRITION – Selected innovations Q4**














#### MEDICAL NUTRITION - IMPROVING DYNAMICS




Price/mix

Volume








- Key dynamics of growth in emerging markets
- Outstanding growth of pediatrics across regions

## MEDICAL NUTRITION – Selected innovations Q4










## TRADING OPERATING INCOME AND MARGIN



€ mIn	FY 2013	FY 2014	
Trading operating income	2,809	2,662	
Other operating items	(681)	(511)	
Operating income	2,128	2,151	
Trading operating margin	13.19%	12.59%	

## 2014 - MARGIN DEVELOPMENT





### 2014 - MANAGING INFLATION THROUGH PRICE & MIX




#### LIKE-FOR-LIKE MARGIN BRIDGE



## **RECORD MILK PRICES**



#### **DANONE FARMGATE PRICE 2006-2014**



# TRADING OPERATING MARGIN by business line & geographical area



€ mIn	FY 2013	FY 2014	Like-for-like change
Fresh Dairy Products	10.35%	9.28%	(67) bps
Waters	13.04%	12.88%	+93 bps
Early Life Nutrition	19.62%	18.83%	(40) bps
Medical Nutrition	18.16%	18.28%	+89 bps
Europe	14.42%	15.67%	+158 bps
CIS+Noram	9.56%	8.56%	(63) bps
ALMA	14.03%	11.60%	(157) bps
Total	13.19%	12.59%	(12) bps


## FROM OPERATING INCOME TO EPS



€ mIn	FY 2013 underlying	FY 2014 underlying	Non-current items	FY 2014
Trading operating income	2,809	2,662		2,662
Other operating items		-	(511)	(511)
Operating income	2,809	2,662	(511)	2,151
Total financial expenses	(311)	(309)	(3)	(312)
Income tax	(750)	(716)	117	(599)
Net income of affiliates	50	66	(52)	14
Net income	1,798	1,703	(450)	1,253
Non-controlling interests	162	142	(7)	134
Net income - Group share	1,636	1,561	(442)	1,119
Fully diluted number of share <i>mln</i>	588	596		
Fully diluted underlying EPS €	€ 2.78	€ 2.62		

## EPS DOWN ON FOREX, UP WITHOUT FOREX AND SCOPE






## CASH BRIDGE




€ mIn




#### **CASH DRIVERS**




#### FREE CASH-FLOW EXCLUDING EXCEPTIONAL ITEMS (€ MLN)



#### WORKING CAPITAL (€ MLN)




#### **CAPITAL EXPENDITURES (€ MLN)**



## 2014 - FCF TO NET DEBT CHANGE




#### € mIn



# A NEW RATING FOR MORE FLEXIBILITY AND A CONFIRMED HIGH-QUALITY SIGNATURE



#### **CHANGE OF RATING**



#### €1.3BN DUAL-TRANCHE BOND ISSUE

Including a tranche of 10-year fixed rate bonds of €750 million, priced at mid swap +48 basis points (coupon of 1.125%).



# SYNTHETIC BALANCE SHEET





- (1) Excluding assets included in net debt
- 2) Net of cash, cash equivalents, marketable securities, other short term investments and financial instrument assets

# 2014 CSR ACHIEVEMENTS: CONTINUING TO BUILD SUSTAINABLE PERFORMANCE





BRINGING HEALTH
THROUGH FOOD TO
AS MANY PEOPLE AS
POSSIBLE



-42 %

Carbon intensity 2008-2014

On track to meet objective of >50% reduction 2008-2020



**-4** %

Water intensity in 2014

On track to meet objective of >60% reduction 2000-2020



-17 %

Lost time accident frequency rate in 2014

From 2,3% in 2013 to 1,9% in 2014

## **AGENDA**



2014: A solid performance in a volatile environment - Pierre-André Terisse, CFO

2015: Priorities and stakes – Emmanuel Faber, CEO

**Questions & Answers** 

## **KEY PRIORITIES SINCE OCTOBER 2014**



#### A NEW EXECUTIVE TEAM



EMMANUEL FABER
Born on January 22, 1954
CEO and Vice-Chairman,
Board of Directors,
appointed to the Executive
Committee in 2000



BERTRAND AUSTRUY
Born on September 15, 1973
General Secretary,
appointed to the Executive
Committee in 2016



MARC BENOÎT
Born on April 8, 1984
Executive Vice President
Human Ressources,
appointed to
the Executive Committee



CÉCILE CABANIS
Born on December 13, 1971
Chief Financial Officer
appointed to the Executive
Committee in 2015



FRANCISCO CAMACHO Born on April 10, 1985 Executive Vice President, Waters, appointed to the Executive Committee in 2011



FELIX MARTIN GARCIA
Born on October 13, 1960
Executive Vice President,
Early Life Nutrition,
appointed to
the Executive Committee



FLEMMING MORGAN
Born on September 29, 1955
Executive Vice President,
Medical Nutrition,
appointed to
the Executive Committee
in 2009



JEAN-PHILIPPE PARÉ Born on August 12,1957 Executive Vice President, Research and Development, appointed to the Executive Committee in 2011



PIERRE-ANDRÉ TERISSE Born an April 20, 1908 Executive Vice President Africa, appointed to the Executive Committee in 2008



GUSTAVO VALLE Born on April 5, 1984 Executive Vice President Fresh Dairy Products, appointed to the Executive Committee in 2015

#### A NEW BUSINESS ORGANIZATION



#### A DEEP DIVE INTO BUSINESS



#### **4 CATEGORIES**









## LEVERAGE OUR STRENGTHS AND OPPORTUNITIES



#### **OUR MISSION**



#### **OUR STRONG BRANDS**



#### **OUR TALENTS**



81% LONG-TERM COMMITMENT

#### **OUR GEOGRAPHICAL FOOTPRINT**



# **DANONE 2020 AS A GUIDING VISION**





# 2015: A FIRST STEP TOWARDS 2020





# **EUROPE - REINFORCE OUR BASE CAMP**







## **EUROPE - FRESH DAIRY PRODUCTS**





#### BREAKDOWN VOLUME/VALUE GROWTH (%)


#### Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 8% 4% 0% (4)% (8)% (12)% Price/mix (16)% Volume


#### 2014 BRANDS PERFORMANCE





#### **RE-INVENT EUROPE**





## **EUROPE - MEDICAL NUTRITION**





#### PERFORMANCE IMPROVEMENT IN A TOUGH CONTEXT

#### RIORMANCE IMI ROVEMENT IN A 100011 CONTEXT

Reimbursement pressure



Competition intensity





#### TRUSTED BRANDS CONTINUOUSLY INNOVATING








#### **NutriApp**

Co-developed with a leading academic centre to monitor calorie and protein intake

#### STRONG LEADER IN WESTERN EUROPE





# NORAM / CIS - TWO POWERHOUSES IN LARGE MARKETS








# NORAM / CIS - FRESH DAIRY PRODUCTS USA






#### LEADING THE YOGURT CATEGORY



#### **CO-LEADING THE GREEK YOGURT SEGMENT**



#### DANNON'S FUTURE GROWTH PILLARS

### CONSUMERS



#### **RETAILERS**



#### **PARTNERS**









# NORAM / CIS - FRESH DAIRY PRODUCTS CIS






#### **RUBLE DEVALUATION**



#### RUSSIAN MILK PRICE INFLATION EVOLUTION



#### **SOLID LOCAL PLATFORM**

Local brands volume >80% of total portfolio







100% local milk sourcing



100% local production

#### 2014 BRANDS SALES GROWTH




growth

# ALMA – A GROWTH PLATFORM FOR TODAY & TOMORROW







# ALMA - LATAM






#### LATAM KEY-DRIVER COUNTRIES



#### **SOLID MODEL BEYOND INFLATION**



#### INNOVATIONS IN ALL BUSINESSES TO DRIVE GROWTH



# ALMA - OPPORTUNITIES OF GROWTH IN ASIA





#### WATERS: BRAND & CATEGORY PERFORMANCE



#### **ELN INDONESIA: A GROWING BUSINESS**



#1 >40% MS with 3 brands







#### A STRATEGIC ALLIANCE WITH MENGNIU







Danone's stake in Mengniu: 9.9%

→ 2<sup>nd</sup> biggest shareholder behind COFCO

- Danone's stake in Mengniu/Danone Dairy joint-venture: 20%
  - #1 in yogurt with 23% MS
  - Top 3 brands: >50 % portfolio
  - Danone's stake in Yashili: 25%



## **ALMA - EARLY LIFE NUTRITION CHINA**

MBS

(Mom & Baby Stores)





#### A BROAD PORTFOLIO COVERING ALL BABIES' NEEDS

# 3 500 3 000 2 500 1 500 1 1 500 1

■ E-commerce

500



#### **NUTRILON: INTENSIFY CONNECTIONS WITH CONSUMERS**









# ALMA – AFRICA, A LAND OF OPPORTUNITIES (AND CHALLENGES)







1 in 4 of the world's children is born in Africa



By 2035, Africa will have a larger working age population than China



40% of Africans are under 15

**1.2 birth** every second in Africa, for a birthrate of 35.4 per 1,000



**Twice** as many mobiles as the US and the most advanced area for mobile money




15 of the fastest growing cities in the world between 2015-2020

# ALMA - AFRICA, BUILDING THE PLATFORM







# A CONTINUED CHALLENGING ENVIRONMENT











# 2015: ENHANCE OUR STRENGTHS AND KEEP BUILDING A SUSTAINABLE MODEL





## 2015 GUIDANCE: ANCHOR THE MODEL






## PROPOSAL TO INCREASE DIVIDEND AT THE NEXT AGM



#### Dividend proposed at the next AGM on April 29th, 2015:

- ✓ € 1.50 per share (+5 ct vs. 2013)
- ✓ Payment in either cash or shares at shareholders' option






# CASH BRIDGE



#### € mIn



# TAX RATE DEVELOPMENT



€ mIn	FY 2013	FY 2014
Total income tax (reported)	(604)	(599)
Reported tax rate	32.4%	32.6%
Non-current income tax <sup>(1)</sup>	146	117
Current income tax	(750)	(716)
Underlying tax rate	30.0%	30.5%

(1) Tax related to non-current items

## SHARE PRICE & SHAREHOLDING




#### DANONE SHARE PRICE EVOLUTION




#### DANONE STOCK PERFORMANCE(1)

Absolute	+4.1%
Relative vs. CAC 40	+3.6%
Relative vs. Eurostoxx 50	+2.9%

#### **SHAREHOLDING BY INVESTOR TYPE (2)**



#### INSTITUTIONAL SHAREHOLDING BY GEOGRAPHY (2)




<sup>(1)</sup> At 31/12/2014

## **ADR PROGRAM**



#### DRs Outstanding as a % of Total Shares Outstanding





\* Ticker: DANOY

\* **CUSIP Number**: 23636T100

Exchange: OTC QX (www.otcqx.com/qx/market/quote?symbol=DANOY)

\* Ratio (ADR: ord): 5:1

Depositary Bank: J.P. Morgan

\* ADR Depositary Bank contact: Jim Reeves +1 212 552 8928 / DRX\_depo@jpmorgan.com

# **IMPACT OF CURRENCIES AND SCOPE - Q4 2014**



	Fresh Dairy Products	Waters	Early Life Nutrition	Medical Nutrition	Total
Reported sales growth	(5.6)%	+14.6%	+29.7%	+10.3%	+5.6%
Currency	(4.0)%	+2.1%	+1.1%	+1.5%	(1.4)%
Scope of consolidation	(0.6)%	+0.2%	+0.5%	+0.1%	(0.5)%
Like-for-like sales growth	(1.0)%	+12.3%	+28.1%	+8.7%	+7.5%

# **IMPACT OF CURRENCIES AND SCOPE - FY 2014**



	Fresh Dairy Products	Waters	Early Life Nutrition	Medical Nutrition	Total
Reported sales growth	(5.6)%	+7.2%	+3.1%	+6.7%	(0.7)%
Currency	(6.9)%	(5.2)%	(3.6)%	(1.4)%	(5.5)%
Scope of consolidation	(0.2)%	+0.8%	+0.6%	+0.2%	+0.1%
Like-for-like sales growth	+1.5%	+11.6%	+6.1%	+7.9%	+4.7%

# Q4 2014 SALES BY BUSINESS & GEOGRAPHICAL AREA



€ mIn	Q4 2013	Q4 2014	Like-for-like sales growth
Fresh Dairy Products	2,854	2,693	(1.0)%
Waters	823	944	+12.3%
Early Life Nutrition	956	1,241	+28.1%
Medical Nutrition	348	384	+8.7%
Europe	1,969	2,105	+4.8%
CIS+Noram	1,170	1,042	+2.0%
ALMA	1,842	2,114	+14.0%
Total	4,981	5,261	+7.5%

# FY 2014 SALES BY BUSINESS & GEOGRAPHICAL AREA



€ mln	FY 2013	FY 2014	Like-for-like sales growth
Fresh Dairy Products	11,790	11,129	+1.5%
Waters	3,903	4,186	+11.6%
Early Life Nutrition	4,263	4,397	+6.1%
Medical Nutrition	1,342	1,432	+7.9%
Europe	8,197	8,522	+2.0%
CIS+Noram	4,713	4,525	+5.0%
ALMA	8,388	8,097	+7.4%
Total	21,298	21,144	+4.7%

# Q4 2014 LIKE-FOR-LIKE SALES GROWTH BREAKDOWN VOLUME/VALUE



Like-for-like	Volume	Price/mix	Total
Fresh Dairy Products	(7.8)%	+6.8%	(1.0)%
Waters	+9.0%	+3.3%	+12.3%
Early Life Nutrition	+11.5%	+16.6%	+28.1%
Medical Nutrition	+6.3%	+2.4%	+8.7%
Europe	+0.0%	+4.8%	+4.8%
CIS+Noram	(8.0)%	+10.0%	+2.0%
ALMA	+3.7%	+10.3%	+14.0%
Total	(0.3)%	+7.8%	+7.5%

# FY 2014 LIKE-FOR-LIKE SALES GROWTH BREAKDOWN VOLUME/VALUE



Like-for-like	Volume	Price/mix	Total
Fresh Dairy Products	(6.6)%	+8.1%	+1.5%
Waters	+7.5%	+4.1%	+11.6%
Early Life Nutrition	+1.7%	+4.4%	+6.1%
Medical Nutrition	+5.6%	+2.3%	+7.9%
Europe	(0.9)%	+2.9%	+2.0%
CIS+Noram	(6.9)%	+11.9%	+5.0%
ALMA	+0.5%	+6.9%	+7.4%
Total	(1.5)%	+6.2%	+4.7%

# **CASH FLOW STATEMENT**



€ mIn	2013	2014
Operating income	2,809	2,662
Financial income	(311)	(309)
Income tax	(750)	(716)
Non-current income	(487)	(397)
Depreciation and amortization	711	956
Net change in provisions	78	(51)
Dividend received from equity accounted affiliates	27	18
Other cash items	(35)	(99)
Other non-cash items	91	90
Cash flow provided by operating activities, excluding changes in net working capital	2,133	2,154

# **CASH FLOW STATEMENT**



€ mIn	2013	2014
Cash flow provided by operating activities, excluding changes in net working capital	2,133	2,154
Change in working capital	224	35
Cash flow from operations	2,357	2,189
Capital expenditure	(1,039)	(984)
Proceeds from the sale of industrial assets	79	67
Business acquisitions and other investments, net of cash and cash equivalent acquired	(1,246)	(1,070)
Proceeds from the sale of businesses	70	34
Change in long-term loans and other long-term assets	(18)	(14)
Cash flow used in investing activities and disposals	(2,155)	(1,966)

# **CASH FLOW STATEMENT**



€ mIn	2013	2014
Increase in capital and additional paid-in capital	37	33
Purchases of treasury stock (net of disposal)	(793)	13
Dividends paid to Danone shareholders	(848)	(307)
Transactions with non controlling interests*	(213)	(471)
Settlement of debt hedge financial instruments	54	(4)
Bonds issued or raised during the period	2,900	150
Bonds repaid during the period	(193)	(618)
Increase (decrease) in other current and non-current financial debt	(111)	312
Increase (decrease) in other short-term investments	(1,176)	535
Cash flow used in financing activities	(344)	(357)
Exchange rate differences	(157)	45
Increase (decrease) in cash	(298)	(89)

<sup>\*</sup> including dividends and capital increase

# CHANGES IN EXCHANGE RATES 28.7% OF SALES DENOMINATED IN €



%	total	FY	14
	sal	es	

FY 14 vs FY 13 (avg)

Q4 14 vs Q4 13 (avg)

US dollar
Russian ruble
Chinese yuan
Indonesian rupiah
British pound
Mexican peso
Brazilian real
Argentine peso
Moroccan Dirham
Polish zloty

10.1%	
9.4%	
6.5%	
5.4%	
5.4%	
5.1%	
4.7%	
4.3%	
2.9%	
2.5%	

(0.1)%
(17.1)%
(0.3)%
(12.0)%
5.3%
(4.0)%
(8.2)%
(32.4)%
0.1%
0.3%

8.9%
(26.2)%
7.9%
2.7%
6.5%
2.5%
(2.6)%
(22.4)%
1.8%
(0.6)%